Century Therapeutics Inc

IPSCNASDAQ · USD
1.16USD0.00 (-11.75%)
1210

Century Therapeutics Inc (IPSC) Implied Volatility Current

IPSC's 30 day implied volatility is 250.68%, with an IV Rank of 55.56%. This is an average IV Rank versus the past year, meaning Century Therapeutics Inc options are fairly priced and currently offer no clear edge to buyers or sellers. IPSC's 30 day historical volatility sits at 110.12%, which means implied volatility is running 140.56 points above historical volatility, as of Nov 20, 2026.

Read more

Tracking IPSC implied volatility helps you spot when Century Therapeutics Inc options are historically cheap or expensive, and where the best trades are hiding. When IPSC IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor IPSC implied volatility current levels in real time and filter for high probability trades.

Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking IPSC IV rank helps you see whether IPSC's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma.

Implied Volatility

IV Rank
55.56%IV Rank
Moderate

IV is slightly elevated. Premiums are richer, leaning toward sellers.

Implied Volatility (30d)250.68%

IV Rank55.56%

Historical Volatility (30d)110.12%

IV Minus HV+140.56%

As of Nov 20, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →